Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodore C Pierson

Showing results (151-160 of 164) with videos related to

Pageof 17
Sort By:
Cell Reports|December 15, 2024
A multidonor class of highly glycan-dependent HIV-1 gp120-gp41 interface-targeting broadly neutralizing antibodiesEvan M Cale, Chen-Hsiang Shen, Adam S Olia, et al.
Science Translational Medicine|June 12, 2020
Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody qualitySonia Maciejewski, Tracy J Ruckwardt, Kaitlyn M Morabito, et al.
Iscience|February 6, 2024
Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer baseHongying Duan, Angela R Corrigan, Cheng Cheng, et al.
Science (New York, N.Y.)|October 7, 2016
Rapid development of a DNA vaccine for Zika virusKimberly A Dowd, Sung-Youl Ko, Kaitlyn M Morabito, et al.
JAMA|April 15, 2020
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical TrialGrace L Chen, Emily E Coates, Sarah H Plummer, et al.
Nature|February 3, 2017
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccinationNorbert Pardi, Michael J Hogan, Rebecca S Pelc, et al.
Nature Microbiology|October 14, 2025
Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza virusesAlexandra A Abu-Shmais, Gray Freeman, Adrian Creanga, et al.
Lancet (London, England)|December 9, 2017
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trialsMartin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, et al.
The Journal of Experimental Medicine|August 18, 2025
Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodiesRyan S Roark, Rumi Habib, Jason Gorman, et al.
Biorxiv : the Preprint Server for Biology|November 19, 2025
Vaccine Elicitation of HIV-1 Neutralizing Antibodies Against Both V2 Apex and Fusion Peptide in Rhesus MacaquesHongying Duan, Joseph P Nkolola, Shuishu Wang, et al.
Pageof 17

Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
Cell Reports|December 15, 2024
A multidonor class of highly glycan-dependent HIV-1 gp120-gp41 interface-targeting broadly neutralizing antibodiesEvan M Cale, Chen-Hsiang Shen, Adam S Olia, et al.
Science Translational Medicine|June 12, 2020
Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody qualitySonia Maciejewski, Tracy J Ruckwardt, Kaitlyn M Morabito, et al.
Iscience|February 6, 2024
Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer baseHongying Duan, Angela R Corrigan, Cheng Cheng, et al.
Science (New York, N.Y.)|October 7, 2016
Rapid development of a DNA vaccine for Zika virusKimberly A Dowd, Sung-Youl Ko, Kaitlyn M Morabito, et al.
JAMA|April 15, 2020
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical TrialGrace L Chen, Emily E Coates, Sarah H Plummer, et al.
Nature|February 3, 2017
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccinationNorbert Pardi, Michael J Hogan, Rebecca S Pelc, et al.
Nature Microbiology|October 14, 2025
Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza virusesAlexandra A Abu-Shmais, Gray Freeman, Adrian Creanga, et al.
Lancet (London, England)|December 9, 2017
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trialsMartin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, et al.
The Journal of Experimental Medicine|August 18, 2025
Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodiesRyan S Roark, Rumi Habib, Jason Gorman, et al.
Biorxiv : the Preprint Server for Biology|November 19, 2025
Vaccine Elicitation of HIV-1 Neutralizing Antibodies Against Both V2 Apex and Fusion Peptide in Rhesus MacaquesHongying Duan, Joseph P Nkolola, Shuishu Wang, et al.
Pageof 17